Trial Profile
A retrospective study investigating efficacy of posaconazole as a primary prophylaxis in patients having breakthrough invasive fungal disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2015
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary)
- Indications Aspergillosis; Fusariosis; Invasive bronchopulmonary aspergillosis; Invasive candidiasis; Mycoses
- Focus Therapeutic Use
- 31 Dec 2015 New trial record